BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18783203)

  • 1. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
    Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
    Ghosh AK; Chapsal BD; Baldridge A; Steffey MP; Walters DE; Koh Y; Amano M; Mitsuya H
    J Med Chem; 2011 Jan; 54(2):622-34. PubMed ID: 21194227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
    Ghosh AK; Jadhav RD; Simpson H; Kovela S; Osswald H; Agniswamy J; Wang YF; Hattori SI; Weber IT; Mitsuya H
    Eur J Med Chem; 2018 Dec; 160():171-182. PubMed ID: 30340140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
    Ghosh AK; Williams JN; Kovela S; Takayama J; Simpson HM; Walters DE; Hattori SI; Aoki M; Mitsuya H
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2565-2570. PubMed ID: 31416666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
    Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
    Ghosh AK; Parham GL; Martyr CD; Nyalapatla PR; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2013 Sep; 56(17):6792-802. PubMed ID: 23947685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
    Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.
    Bai X; Yang Z; Zhu M; Dong B; Zhou L; Zhang G; Wang J; Wang Y
    Eur J Med Chem; 2017 Sep; 137():30-44. PubMed ID: 28554091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
    Ghosh AK; Chapsal BD; Parham GL; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2011 Aug; 54(16):5890-901. PubMed ID: 21800876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.